Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
PubMed
36428621
PubMed Central
PMC9688278
DOI
10.3390/cancers14225530
PII: cancers14225530
Knihovny.cz E-zdroje
- Klíčová slova
- COVID-19, haematological malignancy onset, outcome, prognostic factors, treatment,
- Publikační typ
- časopisecké články MeSH
Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
Aga Khan University 74000 Karachi Pakistan
ASST Grande Ospedale Metropolitano Niguarda 20162 Milan Italy
AZ KLINA 2930 Brasschaat Belgium
Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo 15121 Alessandria Italy
Azienda Ospedaliera San Gerardo Monza 20900 Monza Italy
Centro Hospitalar e Universitário São João 4200 319 Porto Portugal
Communicable Disease Center Hamad Medical Corporation Doha 3050 Qatar
COVID Hospital Batajnica 11000 Belgrade Serbia
Croatian Cooperative Group for Hematological Diseases 10000 Zagreb Croatia
Departament de Medicina Universitat Autònoma de Barcelona 08193 Bellaterra Spain
Department of Hematology Copenhagen University Hospital Rigshospitalet DK 2100 Copenhagen Denmark
Department of Infectious Diseases Karolinska University Hospital 17176 Stockholm Sweden
Department of Internal Medicine ADRZ 4462 RA Goes The Netherlands
Dokuz Eylul University Division of Hematology 35340 Izmir Turkey
Ematologia Con Trapianto Ospedale Dimiccoli Barletta 70051 Barletta Italy
Faculty of Medicine University of Rijeka 51000 Rijeka Croatia
Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD 28040 Madrid Spain
German Centre for Infection Research Partner Site Bonn Cologne 50931 Cologne Germany
Hematology and Stem Cell Transplan Unit Vito Fazzi 73100 Lecce Italy
Hematology Department of Biomedicine and Prevention University of Rome Tor Vergata 00133 Rome Italy
Hematology Unit ASST Spedali Civili 25123 Brescia Italy
Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest 55100 Livorno Italy
Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico 20122 Milan Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS 00168 Rome Italy
Hematology Unit Università Cattolica del Sacro Cuore 86100 Rome Italy
Hospital Escuela de Agudos Dr Ramón Madariaga Posadas 3736 Argentina
Hospital Nuestra Señora de Sonsoles 05004 Ávila Spain
Hospital Universitario de Navarra 31008 Iruña Pamplona Spain
Institute of Hematology and Blood Transfusion 12800 Prague Czech Republic
IRCCS Ospedale San Raffaele 20132 Milan Italy
Laikon Hospital 11527 Athens Greece
Northumbria Healthcare Newcastle NE29 8NH UK
Oncology Center Mansoura University Mansoura 35516 Egypt
Ospedale San Bortolo 36100 Vicenza Italy
Portuguese Institute of Oncology 1099 023 Lisbon Portugal
San Luigi Gonzaga Hospital 10043 Orbassano Italy
School of Medicine University of Zagreb 10000 Zagreb Croatia
Sultan Qaboos University Hospital Muscat 123 Oman
Università Milano Bicocca 20126 Milan Italy
Universitätsklinikum Hamburg Eppendorf 20251 Hamburg Germany
University Hospital Centre Rijeka 51000 Rijeka Croatia
University Hospital Centre Zagreb 10000 Zagreb Croatia
University Hospital Dubrava 10000 Zagreb Croatia
University Hospital Hradec Králové 50005 Hradec Králové Czech Republic
University Hospital Olomouc 77900 Olomouc Czech Republic
University Hospital Ostrava 70852 Ostrava Czech Republic
University Medical Center Groningen 9713 GZ Groningen The Netherlands
UOC Hematology AORN Cardarelli 80131 Naples Italy
Vall d'Hebron Institute of Oncology Vall d'Hebron Barcelona Hospital Campus 08035 Barcelona Spain
Zobrazit více v PubMed
Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., Klimko N., Koehler P., Pagliuca A., Passamonti F., et al. COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA) J. Hematol. Oncol. 2021;14:168. doi: 10.1186/s13045-021-01177-0. PubMed DOI PMC
García-Suárez J., de la Cruz J., Cedillo Á., Llamas P., Duarte R., Jiménez-Yuste V., Hernández-Rivas J.Á., Gil-Manso R., Kwon M., Sánchez-Godoy P., et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J. Hematol. Oncol. 2020;13:133. doi: 10.1186/s13045-020-00970-7. PubMed DOI PMC
Cattaneo C., Daffini R., Pagani C., Salvetti M., Mancini V., Borlenghi E., D’Adda M., Oberti M., Paini A., De Ciuceis C., et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069–5076. doi: 10.1002/cncr.33160. PubMed DOI
Zeidan A.M., Boddu P.C., Patnaik M.M., Bewersdorf J.P., Stahl M., Rampal R.K., Shallis R., Steensma D.P., Savona M.R., Sekeres M.A., et al. Special considerations in the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era: Recommendations from a panel of international experts. Lancet Haematol. 2020;7:e601–e612. doi: 10.1016/S2352-3026(20)30205-2. PubMed DOI PMC
Marchesi F., Salmanton-García J., Emarah Z., Piukovics K., Nucci M., López-García A., Ráčil Z., Farina F., Popova M., Zompi S., et al. COVID-19 in adult acute myeloid leukemia patients: A long-term followup study from the European Hematology Association survey (EPICOVIDEHA) Haematologica. 2022. online ahead of print . PubMed DOI PMC
Hungria V., Garnica M., Crusoé E.D.Q., Filho R.J.P.D.M., Martinez G., Bittencourt R., de Farias D.L.C., Braga W.M., Neto J.V.P., Ribeiro G.N., et al. Managing patients with multiple myeloma during the COVID-19 pandemic: Recommendations from an expert panel–ABHH monoclonal gammopathies committe. Hematol. Transfus. Cell Ther. 2020;42:200–205. doi: 10.1016/j.htct.2020.05.001. PubMed DOI PMC
Grever M., Andritsos L., Banerji V., Barrientos J.C., Bhat S., Blachly J.S., Call T., Cross M., Dearden C., Demeter J., et al. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia. 2021;35:1864–1872. doi: 10.1038/s41375-021-01257-7. PubMed DOI PMC
Lamure S., Salmanton-García J., Marieton E.R., Jaksic O., Kohn M., Marchesi F., Marchetti M., El-Ashwah S., Demirkan F., Valković T., et al. COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022;6:3870–3874. doi: 10.1182/bloodadvances.2022007357. PubMed DOI PMC
Taurino D., Frigeni M., Grassi A., Cavallaro G., Salmoiraghi S., Spinelli O., Rambaldi A., Lussana F. Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: A case report successfully treated with Azacitidine-Venetoclax combination. Mediterr. J. Hematol. Infect. Dis. 2021;13:e2021057. doi: 10.4084/MJHID.2021.057. PubMed DOI PMC
Orf K., Rogosic S., Dexter D., Ancliff P., Badle S., Brierley J., Cheng D., Dalton C., Dixon G., Du Pré P., et al. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. Br. J. Haematol. 2020;190:e274–e276. doi: 10.1111/bjh.17014. PubMed DOI PMC
Ghandili S., Pfefferle S., Roedl K., Sonnemann P., Karagiannis P., Boenisch O., Kluge S., Schmiedel S., Ittrich H., Rohde H., et al. Challenges in treatment of patients with acute leukemia and COVID-19: A series of 12 patients. Blood Adv. 2020;4:5936–5941. doi: 10.1182/bloodadvances.2020002543. PubMed DOI PMC
Salmanton-García J., Busca A., Cornely O.A., Corradini P., Hoenigl M., Klimko N., Marchesi F., Pagliuca A., Passamonti F., Koehler P., et al. EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere. 2021;5:e612. doi: 10.1097/HS9.0000000000000612. PubMed DOI PMC
National Cancer Institute Dictionary of Cancer Terms. [(accessed on 1 May 2022)]; Available online: https://www.cancer.gov/publications/dictionaries/cancer-terms.
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) [(accessed on 1 May 2022)]; Available online: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Palanques-Pastor T., Megías-Vericat J.E., Martínez P., López Lorenzo J.L., Cornago Navascués J., Rodriguez Macias G., Cano I., Arnan Sangerman M., Vidriales Vicente M.B., Algarra Algarra J.L., et al. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: Experience of the PETHEMA group. Leuk. Lymphoma. 2021;62:2928–2938. doi: 10.1080/10428194.2021.1948031. PubMed DOI
Ribera J.-M., Morgades M., Coll R., Barba P., López-Lorenzo J.-L., Montesinos P., Foncillas M.-A., Cabrero M., Gómez-Centurión I., Morales M.-D., et al. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clin. Lymphoma Myeloma Leuk. 2021;21:e801–e809. doi: 10.1016/j.clml.2021.06.024. PubMed DOI PMC
Chiaretti S., Bonifacio M., Agrippino R., Giglio F., Annunziata M., Curti A., Del Principe M.I., Salutari P., Sciumè M., Delia M., et al. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. Haematologica. 2022;107:1955–1959. doi: 10.3324/haematol.2021.280289. PubMed DOI PMC
Yarza R., Bover M., Paredes D., López-López F., Jara-Casas D., Castelo-Loureiro A., Baena J., Mazarico J.M., Folgueira M.D., Meléndez-Carmona M.Á., et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: Analysis of clinical features and predictive factors for severe respiratory failure and death. Eur. J. Cancer. 2020;135:242–250. doi: 10.1016/j.ejca.2020.06.001. PubMed DOI PMC
Ljungman P., de la Camara R., Mikulska M., Tridello G., Aguado B., Zahrani M.A., Apperley J., Berceanu A., Bofarull R.M., Calbacho M., et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicentre prospective survey. Leukemia. 2021;35:2885–2894. doi: 10.1038/s41375-021-01302-5. PubMed DOI PMC
Piñana J.L., Martino R., García-García I., Parody R., Morales M.D., Benzo G., Gómez-Catalan I., Coll R., De La Fuente I., Luna A., et al. Risk factors and outcome of COVID-19 in patients with haematological malignancies. Exp. Hematol. Oncol. 2020;9:21. doi: 10.1186/s40164-020-00177-z. PubMed DOI PMC
Stahl M., Narendra V., Jee J., Derkach A., Maloy M., Geyer M.B., Mato A.R., Roeker L.E., Tallman M.S., Shah G.L., et al. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leuk. Lymphoma. 2021;62:1940–1948. doi: 10.1080/10428194.2021.1885664. PubMed DOI PMC
Cesaro S., Ljungman P., Mikulska M., Hirsch H.H., von Lilienfeld-Toal M., Cordonnier C., Meylan S., Mehra V., Styczynski J., Marchesi F., et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) Leukemia. 2022;36:1467–1480. doi: 10.1038/s41375-022-01578-1. PubMed DOI PMC
Salmanton-García J., Sprute R., Stemler J., Bartoletti M., Dupont D., Valerio M., García-Vidal C., Falces-Romero I., Machado M., de la Villa S., et al. COVID-19–Associated Pulmonary Aspergillosis, March–August 2020. Emerg. Infect. Dis. 2021;27:1077–1086. doi: 10.3201/eid2704.204895. PubMed DOI PMC
Prattes J., Wauters J., Giacobbe D.R., Salmanton-García J., Maertens J., Bourgeois M., Reynders M., Rutsaert L., Van Regenmortel N., Lormans P., et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—A multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. 2022;28:580–587. doi: 10.1016/j.cmi.2021.08.014. PubMed DOI PMC
Zappasodi P., Cattaneo C., Ferretti V., Mina R., Ferreri A.J.M., Merli F., Oberti M., Krampera M., Romano A., Zerbi C., et al. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies a report from the ITA-HEMA-COV. Hematol. Oncol. 2022. online ahead of print . PubMed DOI PMC
Cattaneo C., Pagani C., Cancelli V., Imberti L., Roccaro A.M., Notarangelo L.D., Rossi G. Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time. Leukemia. 2021;35:632–634. doi: 10.1038/s41375-020-01015-1. PubMed DOI PMC
